tbuckley/cabot-search huggingface dataset:
Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials
Authors: Dawn L. Hershman, Cathee Till, Jason D. Wright, Danielle Awad, Scott D. Ramsey, William E. Barlow, Lori M. Minasian, Joseph Unger
Journal: Journal of Clinical Oncology (2016)

Neuropathy is a debilitating toxicity associated with various chemotherapy agents. We evaluated the association between common comorbid conditions and the development of peripheral neuropathy in patients treated with taxane-based chemotherapy.We examined the Southwest Oncology Group database to identify phase II and III trials that included taxane therapy from 1999 to 2011. We linked the Southwest Oncology Group clinical records to Medicare claims data according to Social Security number, sex, and date of birth. The following disease conditions potentially associated with peripheral neuropathy were evaluated: diabetes, hypothyroidism, hypercholesterolemia, hypertension, varicella zoster, peripheral vascular disease, and autoimmune diseases. Multivariate logistic regression was used to model the odds of experiencing grade 2 to 4 neuropathy.A total of 1,401 patients from 23 studies were included in the analysis. Patients receiving paclitaxel were more likely to experience grade 2 to 4 neuropathy compared with docetaxel (25% v 12%, respectively; OR, 2.20; 95% CI, 1.52 to 3.18; P < .001). The inclusion of a platinum agent was also associated with greater neuropathy (OR, 1.68; 95% CI, 1.18 to 2.40; P = .004). For each increase in age of 1 year, the odds of neuropathy increased 4% (P = .006). Patients with complications from diabetes had more than twice the odds of having neuropathy (OR, 2.13; 95% CI, 1.31 to 3.46; P = .002) compared with patients with no diabetes. In contrast, patients with autoimmune disease were half as likely to experience neuropathy (OR, 0.49; 95% CI, 0.24 to 1.02; P = .06). The other conditions were not associated with neuropathy.We found that in addition to drug-related factors, age and history of diabetes were independent predictors of the development of chemotherapy-induced peripheral neuropathy. Interestingly, we also observed that a history of autoimmune disease was associated with reduced odds of neuropathy. Patients with diabetic complications may choose to avoid paclitaxel or taxane plus platinum combination therapies if other efficacious options exist.
Long non-coding RNA HSAT II as a new biomarker for the identification of high risk intraductal papillary mucinous neoplasms (IPMNs)
Authors: F. Pantano, G. Perrone, B. Vincenzi, M. Iuliani, M. Fioramonti, A. Zoccoli, G. Ribelli, D. Borzomati, G. Nappo, C. Pellegrini, M.M. Amato, D. Righi, F.M. Di Matteo, L. Trodella, D. Santini, R. Coppola, A. Onetti-Muda, G. Tonini
Journal: Annals of Oncology (2015)
Myeloid Leukemias Directly Suppress T Cell Proliferation Through STAT3 and Arginase Pathways
Authors: Samantha Miner, Sawa Ito, Kazushi Tanimoto, Nancy F. Hensel, Fariba Chinian, Keyvan Keyvanfar, Christopher S. Hourigan, Minoo Battiwalla, J. Joseph Melenhorst, Pawel Muranski, A. John Barrett
Journal: Blood (2013)
Differences in Reconstitution of NK-Cell Subsets and Expression of Effector Molecules after HLA-Identical and Haploidentical Allogeneic Stem Cell Transplantation in Patients with AML.
Authors: Uwe Platzbecker, Astrid Schulze, Uta Oelschlagel, Holger Schirutschke, Marc Schmitz, Gerhard Ehninger, Martin Bornhauser
Journal: Blood (2005)
Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)
Authors: Simon Rule, Wojciech Jurczak, Mats Jerkeman, Rodrigo Santucci, Chiara Rusconi, Marek Trneny, Fritz Offner, Dolores Caballero, Cristina Joao, Mathias Witzens-Harig, Georg Hess, Isabelle Bence-Bruckler, Seok-Goo Cho, Sriram Balasubramanian, Nibedita Bandyopadhyay, Steven Sun, Jenna Goldberg, John Bothos, Shana Traina, Christopher Enny, Aleksandra Rizo, Jessica Vermeulen, Martin H. Dreyling
Journal: Blood (2015)
PD-016 Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ)
Authors: D.P. Ryan, J. Murphy, D. Mahalingam, J. Strickler, S. Stein, C. Sirard, S. Landau, J. Bendell
Journal: Annals of Oncology (2016)
Case 29-1967
Authors: Eugene Braunwald, Hubert S. Wolfe
Journal: New England Journal of Medicine (1967)

Presentation of CaseA thirty-eight-year-old woman entered the hospital because of orthopnea and ankle edema.She had been well until twenty-five years previously, when she was admitted to the hospital for evaluation of intermittent tenesmus, abdominal cramps and diarrhea. There was no history of rheumatic fever or chorea. Examination disclosed a palpable cardiac thrust and a loud second sound at the cardiac apex, with a systolic murmur extending into early diastole; with the patient in the left lateral decubitus position a third heart sound or a middiastolic murmur was heard. The blood pressure was 118 systolic, 76 diastolic. The hemoglobin . . .
Stitches
Authors: Margaret K Hostetter
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dysfunctional Adipocytes in Cardiovascular Biology239PDE5 inhibition ameliorates visceral adiposity targeting the miR-22 / SIRT1 pathway: evidence from the CECSID trial237AMP-activated protein kinase activation partially restores the anti-contractile effect of perivascular adipose tissue in male offspring of obese dams238Peroxisome proliferator activated receptor (PPAR)alpha-gamma agonist aleglitazar attenuates tumor necrosis factor(TNF)alpha-mediated inflammation and insulin resistance in …
Authors: E Giannetta, KE Zaborska, M Massaro, D Fiore, D Gianfrilli, N Galea, C Di Dato, R Pofi, C Pozza, E Sbardella, I Carbone, F Naro, A Lenzi, M Venneri, AM Isidori, G Edwards, C Austin, M Wareing, E Scoditti, M Pellegrino, MA Carluccio, N Calabriso, M Wabitsch, C Storelli, M Wright, R De Caterina
Journal: Cardiovascular Research (2016)

Background: Visceral adipose plays a significant role in cardiovascular risk.PDE5 inhibitors (PDE5i) can improve cardiac function and insulin sensitivity in type 2 diabetic patients (T2DM).Purpose: To investigate whether PDE5i affect visceral adipose tissue (VAT), specifically epicardial fat (EAT), and what the mechanism involved using microarray-based profiling of pharmacologically modulated miRNAs.Methods: a randomized, double-blid, placebo-controlled study was designed in T2DM.59 diabetic patients were randomized to receive 100 mg/d Sildenafil or Placebo for 12 weeks.Fat biopses were performed in a subgroup of patients.In a parallel animal study, db/db mice were randomized to 12.week Sildenafil or vehicle and VAT was collected.Main outcomes and measures were anthropometric and metabolic parameters, EAT quantification through cardiac magnetic resonance imaging (CMR), array of circulating 2005 miRNAs, qPCR and flow cytometry of VAT.Results: Compared to Placebo, Sildenafil reduced waist circumference (p=0.024) an EAT by CMR (p =0.045).Microarray analysis identified some miRNAs differentially regulate by Sildenafil, among which a downregulation of miR-22-3p, confirmed by real-time qPCR (p,0.0001).Sildenafil's modulation of miR-22-3p was confirmed in vitro in HL-1 cardiomyocytes.An up-regulation of SIRT1, a known target of miR-22-3p was found both in serum and subcutaneous fat in Sildenafil-treated subjects.Compared to vehicle, 12-week Sildenafil treatment downregulated miR-22-3p and upregulated SIRT1 gene expression in VAT from db/db mice, shifting adipose tissue cel composition toward a less inflamed profile.Conclusions: Treatment with PDE5i in human and murine models of diabetes improve VAT targeting SIRT1 through a modulation of miR-22.3pexpression.
Early Alterations in Cardiac Strain in Offspring of Hypertensive Pregnancies: An Echocardiography Study of Infants at Birth and 3 Months
Authors: E F Davis, A J Lewandowski, Y Kenworthy, D X Augustine, C Aye, H Boardman, S Adwani, M Kenny, A Wilkinson, P Leeson
Journal: Circulation (2013)
Effects of Neonicotinoid Pesticide Exposure on Human Health: A Systematic Review
Authors: Andria M. Cimino, Abee L. Boyles, Kristina A. Thayer, Melissa J. Perry
Journal: Environmental Health Perspectives (2016)

Background:Numerous studies have identified detectable levels of neonicotinoids (neonics) in the environment, adverse effects of neonics in many species, including mammals, and pathways through which human exposure to neonics could occur, yet little is known about the human health effects of neonic exposure.Objective:In this systematic review, we sought to identify human population studies on the health effects of neonics.Methods:Studies published in English between 2005 and 2015 were searched using PubMed, Scopus, and Web of Science databases. No restrictions were placed on the type of health outcome assessed. Risk of bias was assessed using guidance developed by the National Toxicology Program's Office of Health Assessment and Translation.Results:Eight studies investigating the human health effects of exposure to neonics were identified. Four examined acute exposure: Three neonic poisoning studies reported two fatalities (n = 1,280 cases) and an occupational exposure study of 19 forestry workers reported no adverse effects. Four general population studies reported associations between chronic neonic exposure and adverse developmental or neurological outcomes, including tetralogy of Fallot (AOR 2.4, 95% CI: 1.1, 5.4), anencephaly (AOR 2.9, 95% CI: 1.0, 8.2), autism spectrum disorder [AOR 1.3, 95% credible interval (CrI): 0.78, 2.2], and a symptom cluster including memory loss and finger tremor (OR 14, 95% CI: 3.5, 57). Reported odds ratios were based on exposed compared to unexposed groups.Conclusions:The studies conducted to date were limited in number with suggestive but methodologically weak findings related to chronic exposure. Given the wide-scale use of neonics, more studies are needed to fully understand their effects on human health.Citation:Cimino AM, Boyles AL, Thayer KA, Perry MJ. 2017. Effects of neonicotinoid pesticide exposure on human health: a systematic review. Environ Health Perspect 125:155–162; http://dx.doi.org/10.1289/EHP515
CLOSED LARYNGEAL INJURIES
Authors: P L KLOTZ
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Development of Small Molecule Inhibitors of the CBFβ-SMMHC Oncoprotein.
Authors: John H. Bushweller, Michael J. Gorczynski, Jolanta Grembecka, Miki Newman, Takeshi Corpora, Yunpeng Zhou, Yali Kong, Jae-Pil Jeon, Pu Paul Liu, Milton L. Brown
Journal: Blood (2005)
Initial Effect of Community-Wide Cytologic Screening on Clinical Stage of Cervical Cancer Detected in an Entire Community. Results of Memphis-Shelby County, Tennessee, Study2
Authors: Raymond F. Kaiser, Cyrus C. Erickson, Bennett E. Everett, Alexander G. Gilliam, Lloyd M. Graves, Mary Walton, Douglas H. Sprunt
Journal: JNCI Journal of the National Cancer Institute (1960)

Cytologic technique was applied to vaginal aspiration smears taken from 151,000 women, including 67.6 percent of the white and 57.3 percent of the Negro population of Memphis and Shelby County, Tennessee, 20 years of age and older. At first screening performed during the 5 years beginning July, 1952, 1.3 cases of unsuspected invasive cervical cancer were detected in each 1,000 white residents screened, and 1.8 cases per 1,000 Negro residents. The prevalence ratios for unsuspected intra-epithelial carcinoma (carcinoma in situ) detected were 3.1 per 1,000 white residents and 4.0 per 1,000 Negroes. The prevalence of unsuspected invasive disease, taken in connection with the presurvey yearly incidence of newly diagnosed cases, provided an estimate that the cytologically detected cases were probably identified, on the average, about 3 years earlier in their invasive phase than the cases diagnosed in the presurvey period. Benefit of the program to the community is indicated by diagnosis of invasive disease at an earlier stage in the entire population. Prior to the screening program, 34 percent of all white patients and 18 percent of all Negro patients in Memphis and Shelby County were in clinical stage I at diagnosis. During the program these proportions increased to 57 and 38 percent, respectively, for the entire population, and to 86 and 77 percent, respectively, for unsuspected cancer cases detected by the screening technique.
A Review of Engineering Approaches for Lymphedema Detection
Authors: Karina Rincon, Pratikkumar Shah, Jessica Ramella-Roman, Shekhar Bhansali
Journal: IEEE Reviews in Biomedical Engineering (2016)

Edema is a condition characterized by excessive swelling of a tissue due to an abnormal accumulation of interstitial fluid in the subcutaneous tissue. More specifically, disruption of the lymphatic system causes what is known as lymphedema. This condition is commonly seen in breast cancer survivors postradiotherapy treatment, chemotherapy, and surgeries; this population has shown high risk of developing lymphedema in the limbs. Throughout the years, several techniques have been developed and implemented for the detection and measurement of lymphedema, including techniques to measure the diseased limb volume, electrical techniques to measure the water content in tissues, and optical techniques to measure either tissue absorbance or limb volume. However, there is still no method that allows for continuous monitoring of the disease and provides a better understanding of its progression. This study describes the different approaches that have been used and that could be used for lymphedema measurement.
Genetically distinct leukemic stem cells in human CD34− acute myeloid leukemia are arrested at a hemopoietic precursor-like stage
Authors: Lynn Quek, Georg W. Otto, Catherine Garnett, Ludovic Lhermitte, Dimitris Karamitros, Bilyana Stoilova, I-Jun Lau, Jessica Doondeea, Batchimeg Usukhbayar, Alison Kennedy, Marlen Metzner, Nicolas Goardon, Adam Ivey, Christopher Allen, Rosemary Gale, Benjamin Davies, Alexander Sternberg, Sally Killick, Hannah Hunter, Paul Cahalin, Andrew Price, Andrew Carr, Mike Griffiths, Paul Virgo, Stephen Mackinnon, David Grimwade, Sylvie Freeman, Nigel Russell, Charles Craddock, Adam Mead, Andrew Peniket, Catherine Porcher, Paresh Vyas
Journal: The Journal of Experimental Medicine (2016)

Our understanding of the perturbation of normal cellular differentiation hierarchies to create tumor-propagating stem cell populations is incomplete. In human acute myeloid leukemia (AML), current models suggest transformation creates leukemic stem cell (LSC) populations arrested at a progenitor-like stage expressing cell surface CD34. We show that in ∼25% of AML, with a distinct genetic mutation pattern where >98% of cells are CD34(-), there are multiple, nonhierarchically arranged CD34(+) and CD34(-) LSC populations. Within CD34(-) and CD34(+) LSC-containing populations, LSC frequencies are similar; there are shared clonal structures and near-identical transcriptional signatures. CD34(-) LSCs have disordered global transcription profiles, but these profiles are enriched for transcriptional signatures of normal CD34(-) mature granulocyte-macrophage precursors, downstream of progenitors. But unlike mature precursors, LSCs express multiple normal stem cell transcriptional regulators previously implicated in LSC function. This suggests a new refined model of the relationship between LSCs and normal hemopoiesis in which the nature of genetic/epigenetic changes determines the disordered transcriptional program, resulting in LSC differentiation arrest at stages that are most like either progenitor or precursor stages of hemopoiesis.
Developing HSCs become Notch independent by the end of maturation in the AGM region
Authors: Céline Souilhol, Javier G. Lendinez, Stanislav Rybtsov, Fiona Murphy, Heather Wilson, David Hills, Antoniana Batsivari, Anahí Binagui-Casas, Alison C. McGarvey, H. Robson MacDonald, Ryoichiro Kageyama, Christian Siebel, Suling Zhao, Alexander Medvinsky
Journal: Blood (2016)
Iron Preparations
Authors: PASQUALE E. PERILLIE
Journal: Annals of Internal Medicine (1976)

Comments and Corrections1 July 1976Iron PreparationsPASQUALE E. PERILLIE, M.D.PASQUALE E. PERILLIE, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-85-1-125_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: These are troubled times for our profession. Malpractice claim settlements and insurance rates are rising. There are greater demands from the public for assurances that we police ourselves to assure them competent care. Editors of outstanding journals such as this one should know that their advertisements serve as one form of medical education for many practicioners. Thus, it disturbs me to find advertisements in this journal recommending the use of iron preparations that are supplied in sustained release packages and have added reducing substances to "enhance iron absorption." Most observant physicians and all hematologists, I am sure,... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: PASQUALE E. PERILLIE, M.D.Affiliations: Department of Medicine Bridgeport Hospital Bridgeport, CT 06602 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 July 1976Volume 85, Issue 1Page: 125-125KeywordsHematology and oncologyMedical education ePublished: 1 December 2008 Issue Published: 1 July 1976 PDF downloadLoading ...
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus surgery-first for resectable pancreatic carcer (Prep-02/JSAP05).
Authors: Michiaki Unno, Fuyuhiko Motoi, Tomoo Kosuge, Hideki Ueno, Hiroki Yamaue, Sohei Satoi, Masayuki Sho, Goro Honda, Ippei Matsumoto, Keita Wada, Junji Furuse, Tohru Furukawa, Kazuyuki Ishida, Kei Takase, Yutaka Matsuyama, Kei Nakagawa, Yu Katayose
Journal: Journal of Clinical Oncology (2015)

TPS4151 Background: Despite the improvements in the surgery and postoperative adjuvant therapy for resected pancreatic adenocarcinoma (PDAC), its prognosis remains poor. Surgery-first and adjuvant increases survival for resected PDAC, but this strategy cannot be offered to a significant proportion of patients due to the unresectable cases found at laparotomy or postoperative morbidity. Neoadjuvant chemotherapy (NAC) with gemcitabine (GEM) and S1 is safe and effective strategy and has been reported 45.7% of 2-year survival rate in an intention-to-treat analysis. Methods: This is a prospective randomized phase II/III trial. Patients who planned resection with cytologically or histologically proven PDAC are eligible for this study. All patients must be at least 20 and under 80 years old with written informed consent. Abutment of major visceral arteries on radiological finding is considered exclusion criteria. Eligible patients will be randomized to surgery followed by adjuvant S1 (80 mg/m2/day for four weeks, repeated similarly every six weeks for a total of four courses) for 6 months or NAC (GEM 1000 mg/m2/week, S1 80 mg/m2/day) followed by surgery and the same adjuvant treatment. NAC is given a total of 4 doses of GEM and 4 weeks of S1 within 8 weeks. The primary study endpoint is resection rate for phase II (n = 80) and overall survival for phase III (n = 280). The secondary endpoints are adverse events and response of NAC, and recurrence-free survival. According to the sample size calculation, 180 patients in total need to be randomized to each treatment arm. For quality control, radiological staging and resected specimen will be centrally reviewed by dedicated radiologists and pathologists, respectively. In phase II part, no more than 14 cases of non-resection (90%CI: 22.6%-49.2%) in each arm (n = 40) is required to transit from phase II to phase III. Enrollment to cohort began in January 2013. Discussion:The Prep-02/JSAP05 study will provide the unbiased overall survival of all PDAC patients who were planned resection. Furthermore, this trial will determine the efficacy of NAC in PDAC and offers a potential for translational research. Clinical trial information: UMIN000009634.
Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer
Authors: Thomas J. Povsic, Monica G. Lawrence, A. Michael Lincoff, Roxana Mehran, Christopher P. Rusconi, Steven L. Zelenkofske, Zhen Huang, Jeffrey Sailstad, Paul W. Armstrong, P. Gabriel Steg, Christoph Bode, Richard C. Becker, John H. Alexander, N. Franklin Adkinson, Arnold I. Levinson
Journal: Journal of Allergy and Clinical Immunology (2016)